Trastuzumab Deruxtecan(Daiichi Sankyo / AstraZeneca)은 Metastatic Salivary Gland Carcinoma 표적 ADC로, Colorectal Cancer; Resectable Colorectal Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting hormone receptor. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 71.7% (ClinicalTrials.gov NCT04739761). 차별점: novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload.
Metastatic Salivary Gland Carcinoma
Colorectal Cancer; Resectable Colorectal Carcinoma
Recruiting
ADC) is a next-generation antibody therapeutics designed to del
deruxtecan (Dato-DXd, Datroway ® )]
cleavable peptide linker and a topoisomerase I payload with byst
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload
targeting hormone receptor
topoisomerase I inhibitor exatecan, as its payload
TROP2 on cancer cell surface and, follow
resistance to ADCs will hopefully help to inform treatment strategies using sequential ADCs in lung cancer and other malignancies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Trastuzumab Deruxtecan(Daiichi Sankyo / AstraZeneca)은 Metastatic Salivary Gland Carcinoma 표적 ADC로, Colorectal Cancer; Resectable Colorectal Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting hormone receptor. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 71.7% (ClinicalTrials.gov NCT04739761). 차별점: novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload.
Metastatic Salivary Gland Carcinoma
Colorectal Cancer; Resectable Colorectal Carcinoma
Recruiting
ADC) is a next-generation antibody therapeutics designed to del
deruxtecan (Dato-DXd, Datroway ® )]
cleavable peptide linker and a topoisomerase I payload with byst
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload
targeting hormone receptor
topoisomerase I inhibitor exatecan, as its payload
TROP2 on cancer cell surface and, follow
resistance to ADCs will hopefully help to inform treatment strategies using sequential ADCs in lung cancer and other malignancies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.